Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Merck Sharp & Dohme LLC
TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc.
Celldex Therapeutics
Jules Bordet Institute
NextCure, Inc.
University of Florida
Klus Pharma Inc.
Tempest Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche